{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:43:11Z","timestamp":1788864191324,"version":"build-2803163510"},"reference-count":36,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-14-1-0161"],"award-info":[{"award-number":["W81XWH-14-1-0161"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","award":["52440"],"award-info":[{"award-number":["52440"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,8,11]]},"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Anti-programmed death 1 (PD1)\/programmed cell death ligand 1 (PD-L1) therapies have shown modest activity as monotherapy in recurrent ovarian cancer. Platinum chemotherapies induce T-cell proliferation and enhance tumor recognition. We assessed activity and safety of pembrolizumab with carboplatin in recurrent platinum-resistant ovarian cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>This phase I\/II, single-arm clinical trial studied concurrent carboplatin and pembrolizumab in recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer. Primary platinum refractory patients were excluded. Patients were treated after progression on subsequent non-platinum systemic therapy after becoming platinum resistant or refractory. Pembrolizumab 200\u2009mg was given on day 1 and carboplatin area under the curve 2 on days 8 and 15 of a 3-week cycle until progression. Imaging was assessed by blinded independent review. PD-L1 expression was assessed by immunohistochemistry. Flow cytometry on peripheral blood mononuclear cells was performed for CD3, CD4, CD8, PD1, CTLA4 and Ki67.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The most common treatment-related adverse events were lymphopenia (18%) and anemia (9%) with most being grade 1 or 2 (93%). Of 29 patients treated, 23 patients were evaluable for best objective response: 10.3% (95% CI 2.2 to 27.4) had partial response (PR), 51.7% (95% CI 32.5 to 70.6) had stable disease (SD). 56.5% of patients had decreases in target lesions from baseline. All PD-L1-positive patients achieved PR (3\/7, 42.8%) or SD (4\/7, 57.2%). Median progression-free survival was 4.63 months (95% CI 4.3 to 4.96). Median OS was 11.3 months (95% CI 6.094 to 16.506). Peripheral CD8+PD1+Ki67+ T cells expanded after 3 (p=0.0015) and 5 (p=0.0023) cycles. CTLA4+PD1+CD8+ T cells decreased through the course of treatment up to the 12th cycle (p=0.004). When stratified by ratio of peripheral CD8+PD1+Ki67+ T cells to tumor burden at baseline, patients with a ratio \u22650.0375\u2009who had a significantly longer median OS of 18.37 months compared with those with a ratio &lt;0.0375\u2009who had a median OS of 8.72 months (p=0.0099). No survival advantage was seen with stratification by tumor burden alone (p=0.24) or by CD8+PD1+Ki67+ T cells alone (p=0.53).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Pembrolizumab with carboplatin was well-tolerated and active in recurrent platinum-resistant ovarian cancer. A ratio of peripheral T-cell exhaustion to radiographic tumor burden may identify patients more likely to benefit from this chemoimmunotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03029598\">NCT03029598<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-003122","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T12:47:28Z","timestamp":1631796448000},"page":"e003122","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct03029598","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3018-7879","authenticated-orcid":false,"given":"John B","family":"Liao","sequence":"first","affiliation":[{"name":"University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R","family":"Gwin","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata R","family":"Urban","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie M","family":"Hitchcock-Bernhardt","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L","family":"Coveler","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen M","family":"Higgins","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S","family":"Childs","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hania N","family":"Shakalia","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron E","family":"Swensen","sequence":"additional","affiliation":[{"name":"Valley Medical Center, Renton, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4300-551X","authenticated-orcid":false,"given":"Sasha E","family":"Stanton","sequence":"additional","affiliation":[{"name":"Providence Cancer Center, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna V","family":"Tinker","sequence":"additional","affiliation":[{"name":"BC Cancer Agency, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya A","family":"Wahl","sequence":"additional","affiliation":[{"name":"Swedish Medical Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G","family":"Ancheta","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn F","family":"McGonigle","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Y","family":"Dai","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary L","family":"Disis","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A","family":"Goff","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"2025100301461663000_9.9.e003122.1","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"2025100301461663000_9.9.e003122.2","doi-asserted-by":"crossref","first-page":"393-401","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of Avelumab for patients with recurrent or refractory ovarian cancer: phase 1B results from the javelin solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100301461663000_9.9.e003122.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3397"},{"key":"2025100301461663000_9.9.e003122.4","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-Arm phases 1 and 2 trial of Niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100301461663000_9.9.e003122.5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025100301461663000_9.9.e003122.6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2020.07.028","article-title":"Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: a phase 2 clinical trial","volume":"159","author":"Lee","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2025100301461663000_9.9.e003122.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02059"},{"key":"2025100301461663000_9.9.e003122.8","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2013.67"},{"key":"2025100301461663000_9.9.e003122.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3141"},{"key":"2025100301461663000_9.9.e003122.10","first-page":"195","article-title":"In vitro effects of platinum compounds on lymphocyte proliferation and cytokine release","volume":"34","author":"Di Gioacchino","year":"2004","journal-title":"Ann Clin Lab Sci"},{"key":"2025100301461663000_9.9.e003122.11","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181628b76"},{"key":"2025100301461663000_9.9.e003122.12","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1038\/s41388-018-0581-9","article-title":"Cisplatin-Induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles","volume":"38","author":"Grabosch","year":"2019","journal-title":"Oncogene"},{"key":"2025100301461663000_9.9.e003122.13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI43656"},{"key":"2025100301461663000_9.9.e003122.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.11.017"},{"key":"2025100301461663000_9.9.e003122.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1433"},{"key":"2025100301461663000_9.9.e003122.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177"},{"key":"2025100301461663000_9.9.e003122.17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509182102"},{"key":"2025100301461663000_9.9.e003122.18","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-10-33","article-title":"Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes","volume":"10","author":"Milne","year":"2012","journal-title":"J Transl Med"},{"key":"2025100301461663000_9.9.e003122.19","doi-asserted-by":"publisher","DOI":"10.1038\/nature22079"},{"key":"2025100301461663000_9.9.e003122.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.027"},{"key":"2025100301461663000_9.9.e003122.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025100301461663000_9.9.e003122.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"2025100301461663000_9.9.e003122.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70049-X"},{"key":"2025100301461663000_9.9.e003122.24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28940"},{"key":"2025100301461663000_9.9.e003122.25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.canlet.2018.01.050","article-title":"Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy","volume":"419","author":"Wu","year":"2018","journal-title":"Cancer Lett"},{"key":"2025100301461663000_9.9.e003122.26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.5511","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: interim results from the phase 2 KEYNOTE-100 study","volume":"36","author":"Matulonis","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"2025100301461663000_9.9.e003122.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(03)00464-5"},{"key":"2025100301461663000_9.9.e003122.28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2018.05.020","article-title":"Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance","volume":"150","author":"Lindemann","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2025100301461663000_9.9.e003122.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.03.005"},{"key":"2025100301461663000_9.9.e003122.30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2017.08.012","article-title":"Fda ovarian cancer clinical trial endpoints workshop: a Society of gynecologic oncology white paper","volume":"147","author":"Herzog","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2025100301461663000_9.9.e003122.31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2019.08.006","article-title":"Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer","volume":"155","author":"Liu","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2025100301461663000_9.9.e003122.32","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"key":"2025100301461663000_9.9.e003122.33","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0039-6109(16)41440-4","article-title":"Intensive surgical and chemotherapeutic management of advanced ovarian cancer","volume":"58","author":"Griffiths","year":"1978","journal-title":"Surg Clin North Am"},{"key":"2025100301461663000_9.9.e003122.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.1953"},{"key":"2025100301461663000_9.9.e003122.35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2657"},{"key":"2025100301461663000_9.9.e003122.36","first-page":"538","article-title":"Early detection of recurrence or progression disease in patients with ovarian cancer after primary debulking surgery. Correlation between CT findings and Ca 125 levels","volume":"69","author":"Giuliani","year":"2017","journal-title":"Minerva Ginecol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:46:27Z","timestamp":1759481187000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,16]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/jitc-2021-003122"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003122","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}